Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

As Ohio cuts off state employees' coverage of medications for weight loss, a lawmaker who has benefited from the drugs wants to bring them back.

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

Just a couple of years ago, Kamloops mom Brandie Bugg was so overweight she couldn’t walk for more than 20 minutes and had to ...

A novel medication out of Sweden has shown some of the same promise in melting belly fat — without making your stomach churn.

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

The former NFL player shared that now that he's lost weight, which was indeed a goal of his, there's one thing that just ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Although Osbourne previously praised Ozempic in December 2022, she has since confessed that she believes she may have taken ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...